Shots:
- Lilly to acquire Disarm for $135M upfront and ~$1.225B as potential development regulatory and commercial milestones, making a total deal value of ~1.36B
- The acquisition will expand Lilly’s R&D efforts in pain and neurodegeneration with the addition of Disarm’s preclinical SARM1 programs for axonal degeneration
- Disarm is advancing its potent SARM1 inhibitors in preclinical development intending to deliver patients with peripheral neuropathy and other neurological diseases like ALS and MS
Click here to read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly
The post Eli Lily to Acquire Disarm Therapeutics for ~.36B first appeared on PharmaShots.
